# Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

> **NCT02415413** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **PETHEMA Foundation** · enrollment: 90 (estimated)

## Conditions studied

- Smoldering Multiple Myeloma

## Interventions

- **DRUG:** carfilzomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT02415413
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-05
- **Primary completion:** 2018-07-05
- **Final completion:** 2027-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-09-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415413, "Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02415413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*